↓ Skip to main content

Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma

Overview of attention for article published in Radiation Oncology, February 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma
Published in
Radiation Oncology, February 2016
DOI 10.1186/s13014-016-0597-7
Pubmed ID
Authors

Eun Kyung Paik, Mi-Sook Kim, Won Il Jang, Young Seok Seo, Chul-Koo Cho, Hyung Jun Yoo, Chul Ju Han, Su Cheol Park, Sang Bum Kim, Young Han Kim

Abstract

This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients. The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter ≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases. Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received non-curative treatments (group 4). The 2-year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %, 73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively. Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving complete response to TACE or receiving curative treatments. However, patients receiving non-curative treatments had significantly lower survival rates than the other groups. Therefore, if SABR was indicated at the initial diagnosis, it might be recommended after TACE failure.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 25%
Student > Master 6 17%
Other 5 14%
Student > Doctoral Student 4 11%
Student > Bachelor 2 6%
Other 3 8%
Unknown 7 19%
Readers by discipline Count As %
Medicine and Dentistry 23 64%
Decision Sciences 1 3%
Agricultural and Biological Sciences 1 3%
Social Sciences 1 3%
Chemistry 1 3%
Other 0 0%
Unknown 9 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2016.
All research outputs
#15,359,595
of 22,849,304 outputs
Outputs from Radiation Oncology
#1,043
of 2,058 outputs
Outputs of similar age
#176,496
of 297,895 outputs
Outputs of similar age from Radiation Oncology
#18
of 50 outputs
Altmetric has tracked 22,849,304 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,058 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 297,895 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.